Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease | Synapse

March 15, 2022Open Access

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

SHSamantha Budd HaeberleinBiogen (United States)PAPaul AisenUniversity College Dublin

Frederik BarkhofUniversity of Siena

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Data from EMERGE demonstrated a statistically significant change across all four primary and secondary clinical endpoints. ENGAGE did not meet its primary or secondary endpoints. A dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease was observed in both trials.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Haeberlein et al. (Tue,) studied this question.

synapsesocial.com/papers/69d74ebff07a12db70b8a95f https://doi.org/https://doi.org/10.14283/jpad.2022.30

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Semiautomated Method for Quantification of F 18 Florbetapir PET Images2015 · 90 citations
2Alzheimer's Disease: The Amyloid Cascade Hypothesis1992 · 7,473 citations
3“Mini-mental state”1975 · 87,151 citations
4The Clinical Dementia Rating (CDR)1993 · 10,019 citations
5Donanemab in Early Alzheimer’s Disease2021 · 1,727 citations